These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 22987603)
1. Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry. Lankheet NA; Hillebrand MJ; Rosing H; Schellens JH; Beijnen JH; Huitema AD Biomed Chromatogr; 2013 Apr; 27(4):466-76. PubMed ID: 22987603 [TBL] [Abstract][Full Text] [Related]
2. Quantification of 11 Therapeutic Kinase Inhibitors in Human Plasma for Therapeutic Drug Monitoring Using Liquid Chromatography Coupled With Tandem Mass Spectrometry. Herbrink M; de Vries N; Rosing H; Huitema AD; Nuijen B; Schellens JH; Beijnen JH Ther Drug Monit; 2016 Dec; 38(6):649-656. PubMed ID: 27749781 [TBL] [Abstract][Full Text] [Related]
3. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856 [TBL] [Abstract][Full Text] [Related]
4. An automated method for the measurement of a range of tyrosine kinase inhibitors in human plasma or serum using turbulent flow liquid chromatography-tandem mass spectrometry. Couchman L; Birch M; Ireland R; Corrigan A; Wickramasinghe S; Josephs D; Spicer J; Flanagan RJ Anal Bioanal Chem; 2012 Jun; 403(6):1685-95. PubMed ID: 22526649 [TBL] [Abstract][Full Text] [Related]
5. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Lankheet AG; Hillebrand MJ; Langenberg MH; Rosing H; Huitema AD; Voest EE; Schellens JH; Beijnen JH J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3625-30. PubMed ID: 19762293 [TBL] [Abstract][Full Text] [Related]
6. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. Andriamanana I; Gana I; Duretz B; Hulin A J Chromatogr B Analyt Technol Biomed Life Sci; 2013 May; 926():83-91. PubMed ID: 23562906 [TBL] [Abstract][Full Text] [Related]
7. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Götze L; Hegele A; Metzelder SK; Renz H; Nockher WA Clin Chim Acta; 2012 Jan; 413(1-2):143-9. PubMed ID: 21945732 [TBL] [Abstract][Full Text] [Related]
8. Development of a high-performance liquid chromatographic-mass spectrometric method for the determination of cellular levels of the tyrosine kinase inhibitors lapatinib and dasatinib. Roche S; McMahon G; Clynes M; O'Connor R J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Dec; 877(31):3982-90. PubMed ID: 19854117 [TBL] [Abstract][Full Text] [Related]
9. Development and Validation of a Simultaneous Quantification Method of 14 Tyrosine Kinase Inhibitors in Human Plasma Using LC-MS/MS. Huynh HH; Pressiat C; Sauvageon H; Madelaine I; Maslanka P; Lebbé C; Thieblemont C; Goldwirt L; Mourah S Ther Drug Monit; 2017 Feb; 39(1):43-54. PubMed ID: 27861317 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring. Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048 [TBL] [Abstract][Full Text] [Related]
11. A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry. van Erp NP; de Wit D; Guchelaar HJ; Gelderblom H; Hessing TJ; Hartigh Jd J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct; 937():33-43. PubMed ID: 24013127 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Bouchet S; Chauzit E; Ducint D; Castaing N; Canal-Raffin M; Moore N; Titier K; Molimard M Clin Chim Acta; 2011 May; 412(11-12):1060-7. PubMed ID: 21345336 [TBL] [Abstract][Full Text] [Related]
13. Simple and selective method for the determination of various tyrosine kinase inhibitors used in the clinical setting by liquid chromatography tandem mass spectrometry. Honeywell R; Yarzadah K; Giovannetti E; Losekoot N; Smit EF; Walraven M; Lind JS; Tibaldi C; Verheul HM; Peters GJ J Chromatogr B Analyt Technol Biomed Life Sci; 2010 May; 878(15-16):1059-68. PubMed ID: 20382575 [TBL] [Abstract][Full Text] [Related]
14. Method development and validation for simultaneous determination of six tyrosine kinase inhibitors and two active metabolites in human plasma/serum using UPLC-MS/MS for therapeutic drug monitoring. Zhang M; Liu X; Chen Z; Jiang S; Wang L; Tao M; Miao L J Pharm Biomed Anal; 2022 Mar; 211():114562. PubMed ID: 35124453 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous quantification of erlotinib, gefitinib, and imatinib in human plasma by liquid chromatography tandem mass spectrometry. Chahbouni A; den Burger JC; Vos RM; Sinjewel A; Wilhelm AJ Ther Drug Monit; 2009 Dec; 31(6):683-7. PubMed ID: 19865001 [TBL] [Abstract][Full Text] [Related]
16. Simultaneous determination of 11 oral targeted antineoplastic drugs and 2 active metabolites by LC-MS/MS in human plasma and its application to therapeutic drug monitoring in cancer patients. Zhao J; Yan D; Li Y; Xu X; Li F; Zhang S; Jin J; Qiu F J Chromatogr B Analyt Technol Biomed Life Sci; 2024 Apr; 1237():124100. PubMed ID: 38547701 [TBL] [Abstract][Full Text] [Related]
17. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. ter Heine R; Alderden-Los CG; Rosing H; Hillebrand MJ; van Gorp EC; Huitema AD; Beijnen JH Rapid Commun Mass Spectrom; 2007; 21(15):2505-14. PubMed ID: 17610214 [TBL] [Abstract][Full Text] [Related]
18. High throughput routine determination of 17 tyrosine kinase inhibitors by LC-MS/MS. Merienne C; Rousset M; Ducint D; Castaing N; Titier K; Molimard M; Bouchet S J Pharm Biomed Anal; 2018 Feb; 150():112-120. PubMed ID: 29220734 [TBL] [Abstract][Full Text] [Related]
19. High-throughput liquid chromatography/electrospray ionization-tandem mass spectrometry method using in-source collision-induced dissociation for simultaneous quantification of imatinib, dasatinib, bosutinib, nilotinib, and ibrutinib in human plasma. Hirasawa T; Kikuchi M; Shigeta K; Takasaki S; Sato Y; Sato T; Ogura J; Onodera K; Fukuhara N; Onishi Y; Maekawa M; Mano N Biomed Chromatogr; 2021 Aug; 35(8):e5124. PubMed ID: 33772839 [TBL] [Abstract][Full Text] [Related]
20. Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma. Aghai F; Zimmermann S; Kurlbaum M; Jung P; Pelzer T; Klinker H; Isberner N; Scherf-Clavel O Anal Bioanal Chem; 2021 Jan; 413(2):599-612. PubMed ID: 33155133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]